100 related articles for article (PubMed ID: 7539635)
1. Influence of FK 506 (tacrolimus) on circulating CD4+ T cells expressing CD25 and CD45RA antigens in 19 patients with chronic progressive multiple sclerosis participating in an open label drug safety trial.
Lemster B; Huang LL; Irish W; Woo J; Carroll PB; Abu-Elmagd K; Rilo HR; Johnson N; Russell-Hall R; Fung JJ
Autoimmunity; 1994; 19(2):89-98. PubMed ID: 7539635
[TBL] [Abstract][Full Text] [Related]
2. Incidence of CD4+ IL-2R alpha+ and CD4+ CD45RA+ T-cells in progressive multiple sclerosis and the influence of short-term (3 months) FK 506 therapy.
Thomson AW; Woo J; Lemster B; Irish W; Huang LL; Carroll PB; Rilo HR; Abu-Elmagd K; Eidelman B
Ann N Y Acad Sci; 1993 Nov; 696():245-9. PubMed ID: 7509133
[No Abstract] [Full Text] [Related]
3. Effect of interleukin-7 and -15 on activation of purified umbilical cord blood and adult peripheral blood CD4+ T cells.
Lin SJ; Cheng PJ
Biol Neonate; 2004; 85(1):3-10. PubMed ID: 14631159
[TBL] [Abstract][Full Text] [Related]
4. Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs.
Putheti P; Pettersson A; Soderstrom M; Link H; Huang YM
J Clin Immunol; 2004 Mar; 24(2):155-61. PubMed ID: 15024182
[TBL] [Abstract][Full Text] [Related]
5. [Change of CCR7 and CD45RA after blocking of Kv1.3 potassium channel of CD4+ T lymphocytes in multiple sclerosis].
Ren XT; Wu WP; Xu QG; Huang DH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(27):1896-9. PubMed ID: 19040002
[TBL] [Abstract][Full Text] [Related]
6. Increased CD69 and human leukocyte antigen-DR expression on T lymphocytes in insulin-dependent diabetes mellitus of long standing.
Gessl A; Waldhäusl W
J Clin Endocrinol Metab; 1998 Jun; 83(6):2204-9. PubMed ID: 9626161
[TBL] [Abstract][Full Text] [Related]
7. In situ activation of helper T cells in the lung.
Raju B; Tung CF; Cheng D; Yousefzadeh N; Condos R; Rom WN; Tse DB
Infect Immun; 2001 Aug; 69(8):4790-8. PubMed ID: 11447152
[TBL] [Abstract][Full Text] [Related]
8. CD45RA+ ICAM-3+ lymphocytes in interferon-beta1b-treated and -untreated patients with relapsing-remitting multiple sclerosis.
Chatzimanolis N; Kraus J; Bauer R; Engelhardt B; Bregenzer T; Kuehne BS; Tofighi J; Laske C; Stolz E; Blaes F; Voigt K; Traupe H; Kaps M; Oschmann P
Acta Neurol Scand; 2004 Dec; 110(6):377-85. PubMed ID: 15527450
[TBL] [Abstract][Full Text] [Related]
9. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans.
Rep MH; van Oosten BW; Roos MT; Adèr HJ; Polman CH; van Lier RA
J Clin Invest; 1997 May; 99(9):2225-31. PubMed ID: 9151795
[TBL] [Abstract][Full Text] [Related]
10. Rapamycin or tacrolimus alone fails to resist cardiac allograft accelerated rejection mediated by alloreactive CD4(+) memory T cells in mice.
Liang H; Liao C; Qi Z; Sha C; Xie B; Chen J; Xia J; Wang Y; Yao Q; Zhao Y
Transpl Immunol; 2010 Feb; 22(3-4):128-36. PubMed ID: 19755159
[TBL] [Abstract][Full Text] [Related]
11. Time-course of interleukin-2 receptor expression in interferon beta-treated multiple sclerosis patients.
Ferrarini AM; Sivieri S; Bulian P; Buttarello M; Biasi G; Tavolato B; Gallo P
J Neuroimmunol; 1998 Apr; 84(2):213-7. PubMed ID: 9628465
[TBL] [Abstract][Full Text] [Related]
12. CD45RA-Foxp3(high) activated/effector regulatory T cells in the CCR7 + CD45RA-CD27 + CD28+central memory subset are decreased in peripheral blood from patients with rheumatoid arthritis.
Matsuki F; Saegusa J; Miyamoto Y; Misaki K; Kumagai S; Morinobu A
Biochem Biophys Res Commun; 2013 Sep; 438(4):778-83. PubMed ID: 23747721
[TBL] [Abstract][Full Text] [Related]
13. Multiple sclerosis: an immune system activation disease.
Macor S; Porrini AM; Giampietro A; Malatesta G; Gambi D
Acta Neurol (Napoli); 1991 Dec; 13(6):590-6. PubMed ID: 1839591
[TBL] [Abstract][Full Text] [Related]
14. Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features.
D'Arena G; Musto P; Cascavilla N; Di Giorgio G; Fusilli S; Zendoli F; Carotenuto M
Haematologica; 1998 Mar; 83(3):197-203. PubMed ID: 9573672
[TBL] [Abstract][Full Text] [Related]
15. Secondary progressive in contrast to relapsing-remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T-cell function and FOXP3 expression.
Venken K; Hellings N; Hensen K; Rummens JL; Medaer R; D'hooghe MB; Dubois B; Raus J; Stinissen P
J Neurosci Res; 2006 Jun; 83(8):1432-46. PubMed ID: 16583400
[TBL] [Abstract][Full Text] [Related]
16. Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Schreiner B; Mitsdoerffer M; Kieseier BC; Chen L; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2004 Oct; 155(1-2):172-82. PubMed ID: 15342209
[TBL] [Abstract][Full Text] [Related]
17. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis.
Khoury SJ; Guttmann CR; Orav EJ; Kikinis R; Jolesz FA; Weiner HL
Arch Neurol; 2000 Aug; 57(8):1183-9. PubMed ID: 10927799
[TBL] [Abstract][Full Text] [Related]
18. Memory and naive CD4+ lymphocytes in multiple sclerosis.
Porrini AM; Gambi D; Malatesta G
J Neurol; 1992 Oct; 239(8):437-40. PubMed ID: 1360022
[TBL] [Abstract][Full Text] [Related]
19. Both CD45RA+ and CD45RA- subpopulations of CD8+ T cells contain cells with high levels of lymphocyte function-associated antigen-1 expression, a phenotype of primed T cells.
Okumura M; Fujii Y; Inada K; Nakahara K; Matsuda H
J Immunol; 1993 Jan; 150(2):429-37. PubMed ID: 7678274
[TBL] [Abstract][Full Text] [Related]
20. Relative impact of CD4+CD25+ regulatory T cells and tacrolimus on inhibition of T-cell proliferation in patients with atopic dermatitis.
Vukmanovic-Stejic M; McQuaid A; Birch KE; Reed JR; Macgregor C; Rustin MH; Akbar AN
Br J Dermatol; 2005 Oct; 153(4):750-7. PubMed ID: 16181456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
